HSBC’s $13.6 Billion Take-Private Offer for Hang Seng Bank Gains Board Backing 
Asian Stocks Slide as AI Valuation Fears and BOJ Uncertainty Weigh on Markets 
RBA Unlikely to Cut Interest Rates in 2026 as Inflation Pressures Persist, Says Westpac 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
Eli Lilly Becomes First Pharma Giant to Hit $1 Trillion Amid Soaring Weight-Loss Drug Demand 
Oil Prices Rebound as Trump Orders Blockade of Sanctioned Venezuelan Tankers 
Tabletop particle accelerator could transform medicine and materials science 
Wall Street Futures Slip as Tech Stocks Struggle Ahead of Key US Economic Data 
Oil Prices Slip in Asia as 2026 Supply Glut Fears and Russia-Ukraine Talks Weigh on Markets 
Trump Signs Executive Order to Boost AI Research in Childhood Cancer 
FDA Lifts REMS Requirement for CAR-T Cell Cancer Therapies 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Bayer’s Stroke Drug Achieves Breakthrough Trial Results, Boosting Market Confidence 
CMOC to Acquire Equinox Gold’s Brazilian Mines in $1 Billion Deal to Expand Precious Metals Portfolio 
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Senate Sets December 8 Vote on Trump’s NASA Nominee Jared Isaacman 
Tokyo Medical and Dental University and the National Center of Neurology and Psychiatry are planning to develop tailored drugs for patients with genetic disorders to find treatment for extremely rare diseases.
The two Japanese medical institutions will search for rare diseases that have the potential to be treated by nucleic acid drugs from a database of around 2,250 patients.
Nucleic acid drugs are an emerging class of therapeutics,
The development will be carried out based on technology that targets the expression of disease-causing proteins in the mutant gene.
Due to the price and challenges with financial viability, pharmaceutical companies are hesitant to develop medications for exceedingly rare disorders.
According to Takanori Yokota, a professor of neurology and neurological science at Tokyo Medical and Dental University, they hope to make effective patient-tailored nucleic acid drugs and find as many people who can be treated.
The Initiative on Rare and Undiagnosed Diseases, a study that examines the DNA of people whose diseases cannot be detected or for which there is no known cure, will be used to pick participants from among the patients registered in it.
The project catalogs approximately 1,700 linked gene sequences and covers a wide spectrum of illnesses, such as neurological, cardiac, and metabolic problems.
In Japan, only one or two family lines are affected by about 70% of the diseases, and many do not have any reliable treatments.
In addition to the causative gene, factors such as age, the severity of symptoms, and the speed at which the disease is progressing will be taken into account when choosing candidate patients.
